Lv63
2520 积分 2022-06-28 加入
Classification System Proposed to Guide the Design, Development, Regulatory Approval, and Scaling of Long Acting, Small and Macro-Molecule Parenteral Products (CS-BLAP)
4小时前
待确认
Strategies for Accelerated Drug Development: An Industry Perspective Based on an IQ Consortium Survey of CMC Considerations
1天前
已完结
CURRENT APPROACHES AND STRATEGIES APPLIED IN FIRST‐IN‐CLASS DRUG DISCOVERY
14天前
已完结
Immunomodulatory in vitro effects of oclacitinib on canine T‐cell proliferation and cytokine production
14天前
已完结
Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis
14天前
已完结
Secrets to successful teams in drug delivery
18天前
已关闭
Unlocking the secrets to Janus kinase activation
21天前
已完结
Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis
1个月前
已完结
Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis
1个月前
已完结
Impact of tubing material on stability and filling accuracy of biologic drug product
3个月前
已完结
皖公网安备34019202002308
